ArticleDrug design, development and therapy2026
Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study aimed to compare the real-world effectiveness and safety of anlotinib plus immune checkpoint inhibitors (ICIs) combination therapy versus chemotherapy in elderly patients with extensive-stage small-cell lung cancer (ES-SCLC). Methods: A total of 119 elderly patients (age ≥65 years) with ES-SCLC were screened and included in this study. Patients who received anlotinib plus ICIs (N = 59) were treated as observation group (OG). Subjects who received single-agent chemotherapy (irinotecan, docetaxel or paclitaxel) (N = 60) were deemed as control group (CG). Overall survival (OS) was the primary endpoint. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), Duration of response (DoR) and tolerability. Kaplan-Meier methods and Log rank tests were used to analyze OS/PFS/DoR with Cox proportional hazards modeling for multivariate analysis. Results: Median age was comparable with 71 years in both groups. Anlotinib plus ICIs showed significantly prolonged survival: median OS was 11.9 months (95% CI: 8.93-14.87) in OG versus 6.7 months (95% CI: 3.41-9.99) in CG (HR=0.53, 95% CI: 0.35-0.81, Conclusion: Anlotinib combined with ICIs demonstrated improved OS compared to single-agent chemotherapy with acceptable safety profile in elderly patients with ES-SCLC. These real-world findings were hypothesis-generating and required confirmation in prospective trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.